Entpd1 Antibody

What is ENTPD1 and why is it important in biomedical research?

ENTPD1 (CD39/NTPDase-1) is a membrane-localized enzyme that hydrolyzes the beta and gamma phosphate residues of nucleotides, with ATP as its preferred substrate. The human version has a canonical length of 510 amino acid residues with a molecular weight of approximately 58 kilodaltons, though six different isoforms have been identified . Initially described as a B lymphocyte cell surface marker, ENTPD1 is also expressed on natural killer cells, T cells, and some endothelial cells .

Its significance in research stems from its regulatory role in purinergic signaling pathways and involvement in thromboregulation and vascular inflammation . Recent studies have also identified ENTPD1 as a potential biomarker linking allergic rhinitis and systemic lupus erythematosus, suggesting broader implications in immune-mediated disorders . The disruption of ENTPD1 function through pathogenic variants has been associated with neurological diseases, including hereditary spastic paraplegia 64 .

What types of ENTPD1 antibodies are available for research applications?

ENTPD1 antibodies are available in various formats optimized for different experimental applications:

When selecting an antibody, consider the experimental application, species cross-reactivity requirements, and whether monoclonal specificity or polyclonal broader epitope recognition would be more suitable for your research question .

What are the most common applications for ENTPD1 antibodies in research?

ENTPD1 antibodies serve multiple research purposes across different experimental techniques:

• Western Blot (WB): Most frequently used application for detecting and quantifying ENTPD1 protein in cell or tissue lysates. Protocols typically employ SDS-PAGE separation followed by transfer to nitrocellulose membrane and probing with ENTPD1-specific antibodies (e.g., Abcam ab108248) .

• Immunohistochemistry (IHC): Enables visualization of ENTPD1 localization within tissue sections, providing insights into its cellular distribution and expression patterns in different physiological or pathological states .

• Flow Cytometry: Critical for identifying and quantifying ENTPD1/CD39 expression on immune cell populations such as B cells, T cells, and NK cells .

• Enzyme-Linked Immunosorbent Assay (ELISA): Allows quantitative measurement of ENTPD1 in biological samples with high sensitivity .

• Immunocytochemistry (ICC): Permits subcellular localization studies of ENTPD1 in cultured cells .

Method selection should be guided by your specific research question, sample type, and required sensitivity level.

How should I optimize Western blot protocols for ENTPD1 detection?

Optimizing Western blot protocols for ENTPD1 detection requires attention to several parameters:

• Sample Preparation: Cell lysis should be performed using radioimmunoprecipitation assay (RIPA) buffer containing protease inhibitors (10 mg/mL each of aprotinin, phenylmethanesulfonyl fluoride, and leupeptin) . This preserves protein integrity while efficiently extracting membrane-bound ENTPD1.

• Protein Loading: Due to ENTPD1's canonical mass of 58 kDa and multiple isoforms, ensure adequate separation by loading 20-40 μg of total protein per lane on 8-12% polyacrylamide gels .

• Transfer Conditions: Efficient transfer of higher molecular weight proteins may require longer transfer times or optimization of buffer composition. For nitrocellulose membranes, a semi-dry transfer at 15V for 30-45 minutes generally yields good results .

• Blocking and Antibody Incubation: Use 5% non-fat dry milk or BSA in TBST for blocking (1 hour at room temperature), followed by overnight incubation at 4°C with primary antibody at manufacturer-recommended dilution (typically 1:1000-1:2000) .

• Detection System: HRP-conjugated secondary antibodies with enhanced chemiluminescence (ECL) substrates provide sensitive detection. For challenging samples, consider signal amplification systems .

• Controls: Include positive controls (cells/tissues known to express ENTPD1) and negative controls (ENTPD1-knockout samples or isotype control antibodies) to validate specificity .

What are the key considerations for using ENTPD1 antibodies in flow cytometry?

When implementing flow cytometry to detect ENTPD1/CD39 expression on immune cells, consider these critical factors:

• Sample Preparation: For peripheral blood analysis, collect samples in EDTA tubes to prevent clotting while preserving surface antigen integrity . Process samples within 24 hours of collection.

• Panel Design: Incorporate CD39/ENTPD1 in multicolor panels that include lineage markers for T cells (CD3, CD4, CD8), B cells (CD19, CD20), NK cells (CD16, CD56), and activation markers (HLA-DR) to comprehensively characterize ENTPD1 expression across immune populations .

• Antibody Titration: Determine optimal antibody concentration through titration experiments to achieve maximum signal-to-noise ratio.

• Controls: Include fluorescence-minus-one (FMO) controls to accurately set gates, particularly important for markers with continuous expression patterns like CD39.

• Instrument Configuration: Use appropriate laser and filter combinations for the selected fluorophore. Common fluorophores for CD39 include PE, APC, and FITC.

• Data Analysis: When analyzing CD39 expression, consider both percentage of positive cells and mean fluorescence intensity (MFI) to capture both frequency and expression level information .

This approach enables detailed characterization of ENTPD1 expression across diverse immune cell subsets in both healthy and pathological contexts.

How can ENTPD1 antibodies be utilized to investigate purinergic signaling pathways?

ENTPD1 antibodies enable sophisticated investigations of purinergic signaling through several experimental approaches:

• Functional Blockade Studies: Blocking antibodies against ENTPD1 can inhibit its enzymatic activity, allowing researchers to assess the impact of unprocessed extracellular ATP/ADP on purinergic receptor activation and downstream signaling events .

• Colocalization Analysis: Dual immunofluorescence labeling with ENTPD1 antibodies and purinergic receptors (P2X, P2Y) can reveal spatial relationships between the enzyme and its signaling partners using confocal microscopy.

• Activity Correlation: Combining ENTPD1 immunodetection with ATP/ADP hydrolysis assays in patient samples can identify relationships between protein expression levels and functional impairment, as demonstrated in studies of ENTPD1-related neurological disorders where impaired ATP/ADP hydrolysis was observed .

• Pathway Analysis: ENTPD1 expression data can be integrated with gene set enrichment analysis (GSEA) to identify associated signaling pathways. For example, ENTPD1 has been linked to KRAS signaling in allergic rhinitis and hypoxia, TGF-beta signaling, and TNF-alpha signaling via NF-kB pathways in systemic lupus erythematosus .

These approaches collectively provide insights into how ENTPD1 regulates extracellular nucleotide levels and modulates downstream purinergic receptor activation in various physiological and pathological contexts.

What methodological approaches can be used to study ENTPD1 in tissue microenvironments?

Studying ENTPD1 in complex tissue microenvironments requires specialized approaches:

• Multiplex Immunohistochemistry/Immunofluorescence: Combining ENTPD1 antibodies with markers for immune cells, endothelial cells, and tissue-specific structures enables spatial mapping of ENTPD1 expression within the tissue architecture. This technique has been successfully applied to analyze ENTPD1 expression in various tissues, including sural nerve biopsies from patients with neurological disorders .

• Laser Capture Microdissection (LCM): This technique can be coupled with ENTPD1 immunostaining to isolate specific ENTPD1-expressing cellular populations from heterogeneous tissues for subsequent molecular analysis.

• Single-Cell Analysis: Flow cytometry or mass cytometry (CyTOF) with ENTPD1 antibodies can characterize ENTPD1 expression at the single-cell level, revealing cellular heterogeneity within tissues.

• Proximity Ligation Assay (PLA): This method can detect in situ protein-protein interactions between ENTPD1 and potential binding partners in tissue sections, providing insights into functional protein complexes.

• Spatial Transcriptomics: Combining ENTPD1 immunodetection with spatial transcriptomics techniques allows correlation of protein expression with transcriptional profiles across tissue regions.

These approaches collectively provide comprehensive insights into ENTPD1's distribution, cell-type specificity, and functional relationships within complex tissue environments.

How do genetic variants in ENTPD1 impact antibody selection and experimental interpretation?

Genetic variants in ENTPD1 present several important considerations for antibody selection and experimental design:

• Epitope Availability: Multiple pathogenic variants have been documented in ENTPD1, including c.398_399delinsAA (p.Gly133Glu), c.540del (p.Thr181Leufs*18), and several others . Truncating mutations or missense variants may alter or eliminate epitopes recognized by specific antibodies. Therefore, antibodies targeting different domains should be selected based on the known variants in your research population.

• Isoform Specificity: Six isoforms of human ENTPD1 have been identified . Researchers should select antibodies that can detect all relevant isoforms or specifically target isoforms of interest, particularly when studying tissues with differential isoform expression.

• Validation Requirements: When studying novel or rare ENTPD1 variants, antibody specificity should be validated using recombinant proteins expressing the variant or cell lines transfected with variant-containing expression vectors.

• Functional Correlation: For variants with potential functional impact (e.g., those associated with neurological disorders), combine immunodetection with functional assays that measure ATP/ADP hydrolysis to correlate protein detection with enzymatic activity .

• Control Selection: Include appropriate genotyped controls when studying variant effects. For Western blot analysis of patient samples with ENTPD1 variants, control protein should be extracted from healthy, unrelated, age-matched control cell lines .

This multifaceted approach ensures accurate detection and interpretation of ENTPD1 variants in research contexts.

How can ENTPD1 antibodies contribute to understanding neurological disorders?

ENTPD1 antibodies provide valuable tools for investigating ENTPD1's role in neurological disorders, particularly hereditary spastic paraplegia 64 (SPG64) and related conditions:

• Expression Profiling: Western blot analysis using ENTPD1 antibodies can quantify expression levels in patient-derived samples compared to controls, revealing potential disease-associated alterations .

• Tissue Distribution Analysis: Immunohistochemical staining of neural tissues (e.g., sural nerve biopsies) with ENTPD1 antibodies can map expression patterns in patients versus controls, identifying tissue-specific abnormalities . This approach revealed altered ENTPD1 distribution in patients with biallelic ENTPD1 variants.

• Functional Correlation Studies: Combining ENTPD1 immunodetection with assays measuring ATP/ADP hydrolysis can establish relationships between protein expression/localization and functional impairment in neurological disease contexts .

• Biomarker Validation: ENTPD1 detection in accessible patient samples (blood, CSF) may serve as a potential biomarker for disease diagnosis, progression monitoring, or treatment response assessment.

• Therapeutic Target Assessment: In experimental models, ENTPD1 antibodies can validate the protein as a therapeutic target and monitor changes in expression during experimental interventions.

These approaches collectively advance understanding of how ENTPD1 dysfunction contributes to neurological pathophysiology and may inform development of targeted therapeutic strategies.

What methodological considerations are important when studying ENTPD1 in immune-mediated disorders?

When investigating ENTPD1 in immune-mediated disorders such as systemic lupus erythematosus (SLE) and allergic rhinitis (AR), several methodological considerations are crucial:

• Immune Cell Subset Analysis: Flow cytometry with ENTPD1 antibodies should be combined with lineage markers to characterize expression across immune cell populations. This approach has revealed positive correlation between ENTPD1 expression and activated CD8 T cells in both SLE and AR .

• Pathway Integration: Gene set enrichment analysis (GSEA) can integrate ENTPD1 expression data with broader pathway information. ENTPD1 has been associated with distinct but overlapping pathways in different disorders—KRAS signaling in AR and hypoxia, TGF-beta signaling, and TNF-alpha signaling via NF-kB in SLE .

• Single-Cell Resolution: Single-cell technologies can reveal heterogeneity in ENTPD1 expression within seemingly homogeneous immune cell populations, potentially identifying disease-relevant cellular subsets.

• Temporal Dynamics: Serial sampling and analysis of ENTPD1 expression during disease progression or treatment may provide insights into its role in disease pathogenesis and response to therapy.

• Functional Validation: Combining ENTPD1 detection with functional assays (ATP/ADP hydrolysis, calcium flux, cytokine production) can connect expression patterns with functional outcomes in disease states.

These methodological approaches collectively enable comprehensive characterization of ENTPD1's role in immune-mediated pathologies and may identify novel therapeutic targets.

What are common technical challenges with ENTPD1 antibodies and how can they be addressed?

Researchers frequently encounter several technical challenges when working with ENTPD1 antibodies:

• Inconsistent Detection in Western Blots:

  • Challenge: Multiple bands or unexpected molecular weights.

  • Solution: ENTPD1 has six identified isoforms and undergoes post-translational modifications . Use positive controls with known expression patterns and consider reducing sample heating time to preserve membrane protein integrity. For glycosylated forms, enzymatic deglycosylation can clarify band patterns.

• Variable Staining Intensity in Immunohistochemistry:

  • Challenge: Inconsistent staining across tissue sections.

  • Solution: Optimize antigen retrieval methods for membrane proteins (citrate buffer, pH 6.0, or EDTA buffer, pH 9.0). For paraffin sections, as used in sural nerve biopsies, standardize fixation time and processing protocols .

• Cross-Reactivity Issues:

  • Challenge: Non-specific binding in certain tissues.

  • Solution: Validate antibody specificity using ENTPD1-knockout controls or competitive blocking with recombinant ENTPD1. Increase washing stringency and optimize blocking conditions using 5% BSA rather than milk for phospho-specific applications.

• Flow Cytometry Signal Variability:

  • Challenge: Inconsistent detection of surface ENTPD1.

  • Solution: Standardize sample processing time (ideally within 24 hours of collection), optimize antibody concentration through titration experiments, and include consistent gating controls across experiments .

• Epitope Masking:

  • Challenge: Reduced antibody binding due to protein interactions.

  • Solution: Consider mild detergent treatment or optimized fixation protocols that preserve epitope accessibility while maintaining cellular architecture.

These approaches should be systematically implemented and documented to establish reproducible ENTPD1 detection protocols.

How should researchers interpret contradictory ENTPD1 expression data across different experimental systems?

When faced with contradictory ENTPD1 expression data across experimental systems, consider these interpretative frameworks:

• Methodological Differences:

  • Different antibodies may target distinct epitopes, potentially affected differently by conformational changes or post-translational modifications.

  • Sample preparation variations (fixation methods, lysis buffers, detergent concentration) can significantly impact membrane protein detection.

  • Systematically compare detection protocols and antibody specifications before concluding biological differences.

• Biological Heterogeneity:

  • ENTPD1 expression varies significantly across tissues and cell types—originally identified on B lymphocytes but also present on NK cells, T cells, and endothelial cells .

  • Expression patterns may change in disease states, as demonstrated in studies linking ENTPD1 to allergic rhinitis and systemic lupus erythematosus .

  • Consider cellular composition and activation state of complex samples.

• Technical Validation Approach:

  • Employ multiple detection methods (WB, flow cytometry, IHC) on the same samples.

  • Use different antibody clones targeting distinct epitopes.

  • Correlate protein detection with functional enzymatic activity (ATP/ADP hydrolysis assays) .

  • Validate with orthogonal approaches (mRNA expression, reporter assays).

• Contextual Interpretation:

  • ENTPD1 functions within complex pathway networks—variations may reflect context-dependent regulation rather than technical artifacts.

  • Consider microenvironmental factors: ENTPD1 in tissue contexts may behave differently than in isolated cell systems.

This multifaceted analytical approach allows researchers to distinguish technical variability from biologically meaningful differences in ENTPD1 expression.

How might ENTPD1 antibodies contribute to developing novel therapeutic approaches?

ENTPD1 antibodies hold significant potential for advancing therapeutic strategies in several disease contexts:

• Target Validation and Monitoring:

  • ENTPD1 antibodies can validate the protein as a therapeutic target in diseases where its dysfunction has been implicated, such as neurological disorders associated with ENTPD1 variants .

  • They can serve as tools to monitor target engagement and expression changes during experimental interventions.

• Therapeutic Antibody Development:

  • Function-modulating antibodies against ENTPD1 could be developed to enhance or inhibit its enzymatic activity in context-dependent applications.

  • The involvement of ENTPD1 in thromboregulation and vascular inflammation suggests potential applications in vascular and transplantation-associated diseases .

• Biomarker Identification:

  • ENTPD1 antibodies can help validate the protein as a biomarker in conditions like allergic rhinitis and systemic lupus erythematosus, potentially enabling early intervention before disease progression .

  • Sequential analysis of ENTPD1 expression during disease progression may identify critical therapeutic windows.

• Targeted Delivery Systems:

  • ENTPD1 antibodies could be incorporated into targeted delivery systems to direct therapeutics specifically to ENTPD1-expressing cells.

  • This approach might be particularly valuable in diseases with tissue-specific ENTPD1 dysregulation.

• Soluble ENTPD1 Production and Monitoring:

  • Antibodies can facilitate the production and quality control of soluble ENTPD1, which has shown therapeutic potential for vascular and transplantation-associated diseases .

These applications collectively highlight the diverse roles ENTPD1 antibodies may play in developing novel therapeutic strategies across multiple disease domains.

What emerging technologies might enhance ENTPD1 antibody-based research in the future?

Several emerging technologies hold promise for advancing ENTPD1 antibody-based research:

• Spatial Multi-omics Integration:

  • Combining ENTPD1 immunodetection with spatial transcriptomics and proteomics will provide comprehensive views of how ENTPD1 expression correlates with broader molecular landscapes in tissue microenvironments.

  • This approach could reveal previously unrecognized relationships between ENTPD1 and other pathways implicated in diseases like systemic lupus erythematosus .

• Advanced Live Cell Imaging:

  • Antibody-based biosensors using fluorescent or luminescent reporters conjugated to anti-ENTPD1 antibody fragments could enable real-time monitoring of ENTPD1 dynamics in living systems.

  • Super-resolution microscopy with ENTPD1 antibodies can provide nanoscale insights into its membrane organization and interactions.

• Antibody Engineering Platforms:

  • Development of high-affinity recombinant antibody fragments (nanobodies, single-chain variable fragments) against ENTPD1 may improve tissue penetration and reduce background in imaging applications.

  • Bispecific antibodies linking ENTPD1 targeting with complementary pathway components could provide novel investigative tools.

• Microfluidic and Organ-on-Chip Technologies:

  • Integrating ENTPD1 antibody-based detection with microfluidic platforms could enable high-throughput analysis of ENTPD1 function under dynamic flow conditions relevant to vascular biology.

  • Organ-on-chip models with real-time ENTPD1 monitoring could recapitulate complex tissue microenvironments for functional studies.

• AI-Enhanced Image Analysis:

  • Machine learning algorithms applied to ENTPD1 immunohistochemistry or immunofluorescence data could identify subtle expression patterns and correlations with disease parameters not apparent through conventional analysis.